Novavax’s stock price surged Friday after the biotech firm started a key late-stage trial of its experimental coronavirus vaccine. Shares in the Maryland-based company soared nearly 11 percent to $113.56 following its Thursday announcement that it kicked off the Phase 3 study in the United Kingdom, which is battling a surge in COVID-19 infections. The…

Read More